Charles Schwab Investment Management Inc Inhibrx, Inc. Transaction History

Charles Schwab Investment Management Inc

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$32.76 - $39.56 $51,367 - $62,030	1,568 Added 0.68%	231,434 $8.09 Million
Q4 2023 Feb 06, 2024	BUY	$14.5 - $38.0 $257,549 - $674,956	17,762 Added 8.37%	229,866 $8.73 Million
Q3 2023 Nov 08, 2023	SELL	$15.75 - $26.31 $535,878 - $895,171	-34,024 Reduced 13.82%	212,104 $3.89 Million
Q2 2023 Aug 09, 2023	BUY	$16.96 - $27.82 $75,081 - $123,159	4,427 Added 1.83%	246,128 $6.39 Million
Q1 2023 May 11, 2023	SELL	$18.45 - $27.14 $114,777 - $168,837	-6,221 Reduced 2.51%	241,701 $4.56 Million
Q4 2022 Feb 13, 2023	BUY	$20.18 - $33.33 $531,864 - $878,445	26,356 Added 11.9%	247,922 $6.11 Million
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $617,630 - $1.32 Million	53,336 Added 31.7%	221,566 $3.98 Million
Q2 2022 Aug 15, 2022	BUY	$8.52 - $25.26 $31,524 - $93,462	3,700 Added 2.25%	168,230 $1.91 Million
Q1 2022 May 13, 2022	BUY	$19.89 - $43.18 $72,001 - $156,311	3,620 Added 2.25%	164,530 $3.67 Million
Q4 2021 Feb 11, 2022	BUY	$26.75 - $46.02 $75,568 - $130,006	2,825 Added 1.79%	160,910 $7.03 Million
Q3 2021 Nov 16, 2021	BUY	$25.18 - $37.81 $1.7 Million - $2.56 Million	67,637 Added 74.78%	158,085 $5.27 Million
Q2 2021 Aug 16, 2021	BUY	$14.69 - $27.52 $572,175 - $1.07 Million	38,950 Added 75.63%	90,448 $2.49 Million
Q1 2021 May 17, 2021	BUY	$16.27 - $41.26 $38,527 - $97,703	2,368 Added 4.82%	51,498 $1.03 Million
Q4 2020 Feb 16, 2021	BUY	$15.96 - $50.0 $784,114 - $2.46 Million	49,130 New	49,130 $1.62 Million

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $565M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.